Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	4	AUG 11	STN AnaVist workshops to be held in North America
NEWS	5	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS	6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS	7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	8	SEP 22	MATHDI to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:09:57 ON 03 OCT 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:10:07 ON 03 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 OCT 2005 HIGHEST RN 864354-42-7
DICTIONARY FILE UPDATES: 2 OCT 2005 HIGHEST RN 864354-42-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\09893585.str



chain nodes :
6 7 8 9 10 11 12 13 14 19 20
ring nodes :
1 2 3 4 5
chain bonds :
1-6 1-10 6-7 6-14 7-8 8-9 10-11 11-12 11-19 12-13 12-20
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-14 7-8 8-9 11-19
exact bonds :
1-6 1-10 10-11 11-12
normalized bonds :
12-13 12-20

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:10:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 100 TO ITERATE

100.0% PROCESSED 100 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1401 TO 2599
PROJECTED ANSWERS: 8 TO 329

L2 8 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 11:10:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2052 TO ITERATE

100.0% PROCESSED 2052 ITERATIONS 173 ANSWERS
SEARCH TIME: 00.00.01

L3 173 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 11:10:58 ON 03 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 3 Oct 2005 VOL 143 ISS 15
FILE LAST UPDATED: 2 Oct 2005 (20051002/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 28 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:611832 CAPLUS
DOCUMENT NUMBER: 143:91081
TITLE: Neutral endopeptidase (NEP) and human soluble endopeptidase (HSEP) inhibitors for prophylaxis and treatment of neurodegenerative disorders
INVENTOR(S): Ikonomidou, Hrissanthi; Turski, Lechoslaw A.; Ziegler, Dieter; Weske, Michael
PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005153936	A1	20050714	US 2005-30043	20050107
WO 2005067937	A1	20050728	WO 2005-EP50075	20050110

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-535538P P 20040112
EP 2004-100067 A 20040112

AB The invention discloses the use of benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivs. having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity. The compds. of the invention are useful for the preparation of pharmaceutical compns. for prophylaxis and treatment of neurodegenerative disorders. The compds. of the invention are known from the European patents EP 0 733 642 and EP 0 916 679.

IT **182821-29-0 182821-29-0D, salts 182821-33-6 182821-33-6D, salts**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivs. for prophylaxis and treatment of neurodegenerative disorders)

RN 182821-29-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-carboxy-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 182821-29-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-carboxy-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182821-33-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-carboxy-4-(1-naphthalenyl)butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182821-33-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-carboxy-4-(1-naphthalenyl)butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:471960 CAPLUS
DOCUMENT NUMBER: 143:13345
TITLE: Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
INVENTOR(S): Thormaehlen, Dirk; Hocher, Berthold; Waldeck, Harald
PATENT ASSIGNEE(S): Solvay Pharmaceuticals G.m.b.H., Germany
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049035	A1	20050602	WO 2004-EP52963	20041115

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005137183	A1	20050623	US 2004-988847	20041116

PRIORITY APPLN. INFO.: EP 2003-104264 A 20031118
US 2003-523106P P 20031119

OTHER SOURCE(S): MARPAT 143:13345

AB The present invention relates to a novel use of benzazepine-N-acetic acid derivs. which contain an oxo-group in the α-position to the nitrogen atom and are substituted in position 3 by a 1-(carboxyalkyl)cyclopentylcarbonylamino radical, and/or of their salts and biolabile esters, and/or of physiol. acceptable solvates thereof, in larger mammals and particularly in humans, preferably human patients having diabetes, and to the production of pharmaceutical compns. and products suitable for the novel treatment. The invention particularly relates to the treatment and/or prophylaxis of renal dysfunction, disease or disorder, preferably in diabetic patients, but in a broader sense also in patients with syndrome X or in particular in patients with a renal dysfunction, disease and /or disorder, which patients are in addition hypertensive, obese, hyperglycemic and/or subject to metabolic disorder.

IT **182560-86-7 182560-97-0 182821-29-0**
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(compns. for the treatment of renal dysfunction in diabetic patients)

RN 182560-86-7 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 182560-97-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, α-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 182821-29-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-carboxy-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:419818 CAPLUS
DOCUMENT NUMBER: 143:125863
TITLE: BRUTUS: Optimization of a Grid-Based Similarity Function for Rigid-Body Molecular Superposition. 1. Alignment and Virtual Screening Applications
AUTHOR(S): Tervo, Anu J.; Roenkkoe, Toni; Nyroenen, Tommi H.; Poso, Antti
CORPORATE SOURCE: Department of Pharmaceutical Chemistry, University of Kuopio, Kuopio, 70211, Finland
SOURCE: Journal of Medicinal Chemistry (2005), 48(12), 4076-4086
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have developed a fast grid-based algorithm, BRUTUS, for rigid-body mol. superposition and similarity searching. BRUTUS aligns mols. using field information derived from charge distributions and van der Waals shapes of the compds. Mols. can have similar biol. properties if their charge distributions and shapes are similar, even though they have different chemical structures; i.e., BRUTUS can identify compds. possessing similar properties, regardless of their structures. In this paper, we present two applications of BRUTUS. First, BRUTUS was used to superimpose five sets of inhibitors. Second, two sets of known inhibitors were searched from a database, and the results were analyzed using self-organizing maps. We demonstrate that BRUTUS is successful in superimposing compds. using mol. fields and, importantly, is fast and accurate enough for virtual screening of chemical databases using a standard personal computer. This fast and efficient mol.-field-based algorithm is applicable for virtual screening of structurally diverse, active mols.

IT 129980-23-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BRUTUS algorithm for rigid-body mol. superposition and similarity searching)

RN 129980-23-0 CAPLUS
CN L-Tryptophan, N-[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:300468 CAPLUS
DOCUMENT NUMBER: 142:373707
TITLE: Preparation of aminocarbonylpropylcyclopentanecarbonyl amino oxobenzazepineacetates as inhibitors of neutral and human soluble endopeptidases for the treatment of cardiovascular disease, hypertension, sexual dysfunction, and apoptosis and as neuroprotective agents
INVENTOR(S): Hoeltje, Dagmar; Fischer, Yvan; Ziegler, Dieter; Weske, Michael; Michaelis, Kathrin; Karimi-Nejad, Yasmin; Messinger, Josef; Pahl, Axel; Hoefer, Constanze; Ikonomidou, Hrissanthi; Turski, Lechoslaw
PATENT ASSIGNEE(S): Solvay Pharmaceuticals G.m.b.H., Germany
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030795	A1	20050407	WO 2004-EP52289	20040923
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10344848	A1	20050414	DE 2003-10344848	20030926
US 2005119247	A1	20050602	US 2004-948843	20040924
PRIORITY APPLN. INFO.:			DE 2003-10344848 A	20030926
			EP 2004-100065 A	20040112
			US 2003-530990P P	20031222
			US 2004-535505P P	20040112

OTHER SOURCE(S): MARPAT 142:373707
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB (carboxyl)aminocarbonylpropyl cyclopentanecarbonylamino-substituted oxobenzazepineacetates I [R1 = H, biolabile moiety; R2 = H, alkyl, (un)substituted hydroxyalkyl; R3 = alkyl, (un)substituted alkoxyalkyl, hydroxyalkyl; NR2R3 = (un)substituted heterocyclyl; R4 = H, biolabile moiety] such as II are prepared as inhibitors of neutral and human soluble endopeptidases for the treatment of cardiovascular disease, hypertension, sexual dysfunction, and apoptosis and for use as neuroprotective agents. Benzyl alc. and itaconic acid anhydride react regioselectively to give PhCH2O2CCH2C(:CH2)CO2H which is esterified with ethanol followed by Michael addition of the dienolate of cyclopentanecarboxylic acid to give the substituted cyclopentanecarboxylic acid III; amidation of III with the

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

nonracemic aminooxobenzazepineacetate IV, hydrogenolysis of the benzyl group, and sepn. of the diastereomers by preparative HPLC, amidation with isopropylamine, and hydrolysis of the Et and tert-Bu esters yields II and its aminocarbonylpropyl side chain diastereomer. Biol. data for the inhibition of neutral endopeptidase and human sol. endopeptidase by some of the title compds. and for the antihypertensive, antiapoptotic, and neuroprotective activities of some of the title compds. are given. Methods for the prepn. of the title compds. are claimed.

IT **849631-65-8P 849631-66-9P 849631-68-1P**
849631-68-5P 849632-20-8P 849632-25-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aminocarbonylpropylcyclopentanecarbonylamino oxobenzazepineacetates as inhibitors of endopeptidase for the treatment of hypertension, sexual dysfunction, apoptosis, and brain damage)

RN 849631-65-8 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-carboxy-4-[(3-hydroxypropyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-66-9 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2S)-2-carboxy-4-[(3-hydroxypropyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-68-1 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[(1-methylethyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, α-(1,1-dimethylethyl) ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849631-88-5 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[methyl(1-methylethyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-20-8 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[(3-aminopropyl)ethylamino]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-25-3 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[methyl(1-methylethyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, α-ethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 849631-39-6P 849631-40-9P 849631-41-0P
849631-42-1P 849631-43-2P 849631-44-3P
849631-45-4P 849631-46-5P 849631-47-6P
849631-48-7P 849631-49-8P 849631-50-1P
849631-51-2P 849631-52-3P 849631-53-4P
849631-54-5P 849631-55-6P 849631-56-7P
849631-58-9P 849631-59-0P 849631-67-0P
849631-72-7P 849631-74-9P 849631-76-1P
849631-77-2P 849631-78-3P 849631-79-4P
849631-80-7P 849631-81-8P 849631-82-9P
849631-83-0P 849631-84-1P 849631-85-2P
849631-97-6P 849631-99-8P 849632-01-5P
849632-05-9P 849632-06-0P 849632-07-1P
849632-08-2P 849632-10-6P 849632-11-7P
849632-12-8P 849632-13-9P 849632-14-0P
849632-15-1P 849632-16-2P 849632-19-5P
849632-21-9P 849632-23-1P 849632-27-5P
849632-28-6P 849632-29-7P 849632-30-0P
849632-31-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminocarbonylpropylcyclopentanecarbonylamino oxobenzazepineacetates as inhibitors of endopeptidase for the treatment of hypertension, sexual dysfunction, apoptosis, and brain damage)

RN 849631-39-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(methyl(1-methylethyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 849631-40-9 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(dimethylamino)-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 849631-41-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(diethylamino)-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 849631-42-1 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[(2-hydroxyethyl)methylamino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 849631-43-2 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[(3-hydroxypropyl)methylamino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849631-44-3 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(4-hydroxy-1-piperidinyl)-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 849631-45-4 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[4-[(2S)-2-amino-3-methyl-1-oxobutoxy]-1-piperidinyl]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-46-5 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(4-morpholinyl)-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849631-47-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-oxo-4-(4-oxo-1-piperidinyl)butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 849631-48-7 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[bis(2-hydroxyethyl)amino]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849631-49-8 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[ethyl[3-(ethylamino)propyl]amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 849631-50-1 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[[2-(dimethylamino)ethyl]methylamino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 849631-51-2 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[(3-aminopropyl)ethylamino]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849631-52-3 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[methyl[2-(methylamino)ethyl]amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 849631-53-4 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[(4-aminobutyl)methylamino]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 849631-54-5 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[(4-aminobutyl)ethylamino]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 849631-55-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[methyl[3-(methylamino)propyl]amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 849631-56-7 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[(5-aminopentyl)methylamino]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 849631-58-9 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-carboxy-4-[(1-methylethyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-59-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2S)-2-carboxy-4-[(1-methylethyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849631-67-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[(3-hydroxypropyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, α-ethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-72-7 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[(2-methoxyethyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-74-9 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[(hexahydro-2-oxo-1H-azepin-3-yl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849631-79-4 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-oxo-4-[(2-oxo-2-phenylethyl)amino]butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-80-7 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[(cyclopropylmethyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-81-8 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[[(4-methoxyphenyl)methyl]amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849631-76-1 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(4-morpholinyl)-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-77-2 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[[2-(4-methoxyphenyl)-2-oxoethyl]amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-78-3 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[(1,1-dimethyl-3-oxobutyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849631-82-9 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[[2-(4-methoxyphenyl)ethyl]amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-83-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[[(2-methoxyphenyl)methyl]amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-84-1 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-oxo-4-[(phenylmethyl)amino]butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849631-85-2 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(methylamino)-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-97-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[(1-methylethyl)amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, α-[(2-methoxyethoxy)methyl] ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849631-99-8 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[(2-hydroxyethyl)methylamino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849632-01-5 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-oxo-4-(4-oxo-1-piperidinyl)butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-05-9 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-oxo-4-(1-pyrrolidinyl)butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-06-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[3-(hydroxymethyl)-1-piperidinyl]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849632-07-1 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[(2,3-dihydroxypropyl)methylamino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-08-2 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[ethyl[3-(ethylamino)propyl]amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-10-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(dimethylamino)-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849632-11-7 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(diethylamino)-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-12-8 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[(3-hydroxypropyl)methylamino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-13-9 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(4-hydroxy-1-piperidinyl)-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849632-14-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[bis(2-hydroxyethyl)amino]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-15-1 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[[2-(dimethylamino)ethyl]methylamino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-16-2 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[[3-(dimethylamino)propyl]methylamino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849632-19-5 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[(3-aminopropyl)methylamino]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-21-9 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[methyl[2-(methylamino)ethyl]amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-23-1 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[4-[(2S)-2-amino-3-methyl-1-oxobutoxy]-1-piperidinyl]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849632-27-5 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[(4-aminobutyl)methylamino]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-28-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[(4-aminobutyl)ethylamino]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-29-7 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-[methyl[3-(methylamino)propyl]amino]-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 849632-30-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[(5-aminopentyl)methylamino]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849632-31-1 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[4-[(5-aminopentyl)ethylamino]-2-carboxy-4-oxobutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 849632-33-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(drug candidate; preparation of aminocarbonylpropylcyclopentanecarbonylamino oxobenzazepineacetates as inhibitors of endopeptidase for the treatment of hypertension, sexual dysfunction, apoptosis, and brain damage)

RN 849632-33-3 CAPLUS
CN Butanedioic acid, [[1-[[[(3S)-1-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]amino]carbonyl]cyclopentyl]methyl]-, 4-methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **849632-35-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of aminocarbonylpropylcyclopentanecarbonylamino oxobenzazepineacetates as inhibitors of endopeptidase for the treatment of hypertension, sexual dysfunction, apoptosis, and brain damage)
RN 849632-35-5 CAPLUS
CN Butanedioic acid, [[1-[[[(3S)-1-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]amino]carbonyl]cyclopentyl]methyl]-, 4-methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:158503 CAPLUS
DOCUMENT NUMBER: 142:254628
TITLE: Compositions of a chromene or phenylacetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
INVENTOR(S): Stephenson, Diane T.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016249	A2	20050224	WO 2004-US21744	20040708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005070543	A1	20050331	US 2004-887022	20040708
PRIORITY APPLN. INFO.:			US 2003-486300P	P 20030711
OTHER SOURCE(S):		MARPAT 142:254628		

AB The invention provides compns. and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of an ACE inhibitor in combination with a chromene or phenylacetic acid cyclooxygenase-2 selective inhibitor.
IT **129980-23-0 129980-23-0D**, isomers, esters, salts, or prodrug derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chromene or phenylacetic acid cyclooxygenase-2 selective inhibitor-ACE inhibitor combination for treatment of central nervous system damage)
RN 129980-23-0 CAPLUS
CN L-Tryptophan, N-[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 129980-23-0 CAPLUS
CN L-Tryptophan, N-[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1035011 CAPLUS
DOCUMENT NUMBER: 142:33016
TITLE: Neutral endopeptidase inhibitors for the treatment of female sexual dysfunction
INVENTOR(S): Maw, Graham Nigel; Wayman, Christopher Peter
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: Eur. Pat. Appl., 134 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1481667	A1	20041201	EP 2004-20972	20001103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI, CY, TR				
EP 1097719	A1	20010509	EP 2000-309722	20001103
EP 1097719	B1	20041222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
ES 2233297	T3	20050616	ES 2000-309722	20001103
ZA 2000006374	A	20020506	ZA 2000-6374	20001106
ZA 2000006375	A	20020506	ZA 2000-6375	20001106
ZA 2000006376	A	20020506	ZA 2000-6376	20001106
ZA 2000006378	A	20020506	ZA 2000-6378	20001106
US 6734186	B1	20040511	US 2000-708392	20001108
US 2004254153	A1	20041216	US 2003-686390	20031015
US 2005020547	A1	20050127	US 2003-686282	20031015
US 2005070499	A1	20050331	US 2003-686349	20031015
JP 2005013237	A2	20050120	JP 2004-268608	20040915
JP 2005021167	A2	20050127	JP 2004-267669	20040915
JP 2005043377	A2	20050217	JP 2004-269807	20040916
JP 2005070055	A2	20050317	JP 2004-269732	20040916
PRIORITY APPLN. INFO.:			GB 1999-26437	A 19991108
			GB 2000-4021	A 20000218
			GB 2000-13001	A 20000526
			GB 2000-16563	A 20000705
			GB 2000-17141	A 20000712
			EP 2000-309722	A3 20001103
			US 2000-175161P	P 20000107
			US 2000-192962P	P 20000329
			US 2000-217479P	P 20000711
			US 2000-221014P	P 20000727
			US 2000-221093P	P 20000727
			JP 2000-339853	A3 20001108
			JP 2000-339905	A3 20001108
			JP 2000-339949	A3 20001108
			JP 2000-339957	A3 20001108
			US 2000-708392	A3 20001108

GI

L4 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

AB A method of treating a female suffering from female sexual dysfunction, in particular female sexual arousal disorder, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia, wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. The agent is an inhibitor of neutral endopeptidase.

Preparation
of selected compds., e.g. I, is included.

IT **337962-68-2P 337962-71-7P 337962-76-2P**
337962-93-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neutral endopeptidase inhibitors for treatment of female sexual dysfunction)

RN 337962-68-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 337962-71-7 CAPLUS
CN Benzenebutanoic acid, α-[[1-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 337962-76-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



RN 337962-93-3 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



IT **337962-89-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(neutral endopeptidase inhibitors for treatment of female sexual dysfunction)

RN 337962-89-7 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:546487 CAPLUS
DOCUMENT NUMBER: 141:106453
TITLE: Preparation of cyclopentyl glutaramide derivs. as neutral endopeptidase inhibitors
INVENTOR(S): Dack, Kevin Neil; Owen, Dafydd Rhys; Watson, Christine Anne Louise
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056787	A1	20040708	WO 2003-IB5981	20031212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2511360	AA	20040708	CA 2003-2511360	20031212
EP 1578735	A1	20050928	EP 2003-778633	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004138274	A1	20040715	US 2003-739426	20031218
NL 1025116	A1	20040624	NL 2003-1025116	20031223
NL 1025116	C2	20041018		

PRIORITY APPLN. INFO.:
GB 2002-30025 A 20021223
US 2003-448224P P 20030218
WO 2003-IB5981 W 20031212

OTHER SOURCE(S): MARPAT 141:106453
GI

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB The title compds. I [R1 = C1-C6alkyl, C1-C6alkoxyC1-C3alkyl, or C1-C6alkoxyC1-C6alkoxyC1-C3alkyl; R2 = H or C1-C6alkyl; L = an aromatic heterocyclic ring, optionally substituted with C1-C6alkyl or halo; R3 = C1-C6alkyl optionally substituted by halo, alkoxy, haloalkoxy, alkylthio, haloalkylthio or nitrile group, or R3 is Ph or aromatic heterocyclyl each of which may be independently substituted by one or more alkyl, halo, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio or nitrile group; R4, R5 = either both hydrogen, or one of R4 and R5 is hydrogen and the other is a biolabile ester; p = 0-2; and q = 1 or 2] were prepared as neutral endopeptidase inhibitors for the treatment of cardiovascular disorders or related diseases. For example, reaction of (2S)-2-Amino-3-[5-(4-chlorophenyl)-oxazol-2-yl]-propionic acid Et ester hydrochloride (preparation given) and 1-[(2S)-2-(tert-butoxycarbonyl)-4-methoxybutyl]cyclopentanecarboxylic acid yielded (2S)-2-{1-[(1S)-1-Ethoxycarbonyl-2-(4-methyl-5-phenyl-oxazol-2-yl)-ethylcarbamoyl]-cyclopentylmethyl}-4-methoxy-butyric acid tert Bu ester, which when treated with trifluoroacetic acid furnished compound II. The prepared compds. are potent inhibitors of neutral endopeptidase.

IT **719307-43-4P 719307-46-7P 719307-55-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cyclopentyl glutaramide derivs. as neutral endopeptidase inhibitors)

RN 719307-43-4 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-4-methyl-5-phenyl-, monoethyl

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-46-7 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-5-phenyl-, monoethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-55-8 CAPLUS
CN 4-Oxazolepropanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-5-phenyl-, monoethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **719307-44-5P 719307-45-6P 719307-47-8P**
719307-48-9P 719307-49-0P 719307-50-3P
719307-51-4P 719307-52-5P 719307-53-6P
719307-54-7P 719307-56-9P 719307-59-2P
719307-60-5P 719307-61-6P 719307-62-7P
719307-63-8P 719307-64-9P 719307-65-0P

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
719307-66-1P 719307-67-2P 719307-68-3P
719307-69-4P 719307-70-7P 719307-71-8P
719307-72-9P 719307-73-0P 719307-74-1P
719307-75-2P 719307-76-3P 719307-77-4P
719307-78-5P 719307-79-6P 719307-80-9P
719307-81-0P 719307-82-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of cyclopentyl glutaramide derivs. as neutral endopeptidase inhibitors)

RN 719307-44-5 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-(4-fluorophenyl)-, monoethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-45-6 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-phenyl-, monoethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-47-8 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-(4-chlorophenyl)-, monoethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 719307-48-9 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-phenyl-, mono(2-methylpropyl) ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-49-0 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-phenyl-, mono(1-methylethyl) ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-50-3 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-4-phenyl-, monoethyl ester, (αS)- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry. Rotation (-).



RN 719307-51-4 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-phenyl-, monopropyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-52-5 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-phenyl-, monobutyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2-Oxazolebutanoic acid, β-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-5-phenyl-, α-ethyl ester, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-59-2 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-phenyl-, monocyclopentyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-60-5 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-phenyl-, mono(1-ethylpropyl) ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 719307-53-6 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-phenyl-, mono(phenylmethyl) ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-54-7 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-4-phenyl-, monoethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-56-9 CAPLUS

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 719307-61-6 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-phenyl-, mono(2-butoxyethyl) ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-62-7 CAPLUS
CN 1H-Imidazole-1-propanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-4-phenyl-, monoethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-63-8 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-5-phenyl-, monobutyl ester, (αS)- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry. Rotation (-).



RN 719307-64-9 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-5-phenyl-, monopropyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-65-0 CAPLUS
CN 1H-Imidazole-1-propanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-4-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-66-1 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-70-7 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-5-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-71-8 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-(4-chlorophenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-72-9 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-4-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methoxybutyl]cyclopentyl]carbonyl]amino]-4-methyl-5-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-67-2 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-(4-fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-68-3 CAPLUS
CN 2-Oxazolebutanoic acid, β-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-5-phenyl-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-69-4 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-3-phenyl-, (αS)- (9CI) (CA

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 719307-73-0 CAPLUS
CN 5-Oxazolepropanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-2-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-74-1 CAPLUS
CN 4-Oxazolepropanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-5-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-75-2 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-4-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-76-3 CAPLUS

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1,2,4-Oxadiazole-3-propanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719307-77-4 CAPLUS
CN 1H-Pyrazole-1-propanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-4-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 719307-78-5 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-4-(2-methylpropyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-79-6 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-4-ethyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 719307-80-9 CAPLUS
CN 1,3,4-Oxadiazole-2-propanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-81-0 CAPLUS
CN 2-Oxazolepropanoic acid, α-[[[1-[(2S)-2-carboxy-4-methoxybutyl]cyclopentyl]carbonyl]amino]-5-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 719307-82-1 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, α-[[[1-[(2R)-2-carboxypentyl]cyclopentyl]carbonyl]amino]-3-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L4 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:188456 CAPLUS
DOCUMENT NUMBER: 140:368095
TITLE: SURFCOMP: A Novel Graph-Based Approach to Molecular Surface Comparison
AUTHOR(S): Hofbauer, Christian; Lohninger, Hans; Aszodi, Andras
CORPORATE SOURCE: Novartis Institutes for BioMedical Research, Vienna, A-1235, Austria
SOURCE: Journal of Chemical Information and Computer Sciences (2004), 44(3), 837-847
CODEN: JCISD8; ISSN: 0095-2338
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Anal. of the distributions of physicochem. properties mapped onto mol. surfaces can highlight important similarities or differences between compound classes, contributing to rational drug design efforts. Here the authors present an approach that uses maximal common subgraph comparison and harmonic shape image matching to detect locally similar regions between two mol. surfaces augmented with properties such as the electrostatic potential or lipophilicity. The complexity of the problem is reduced by a set of filters that implement various geometric and physicochem. heuristics. The approach was tested on dihydrofolate reductase and thermolysin inhibitors and was shown to recover the correct alignments of the compds. bound in the active sites.

IT 129980-23-0
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(SURFCOMP as novel graph-based approach to mol. surface comparison in drug design applied to dihydrofolate reductase and thermolysin inhibitors to determination alignments of compds. to active sites)

RN 129980-23-0 CAPLUS
CN L-Tryptophan, N-[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:869567 CAPLUS
DOCUMENT NUMBER: 137:370356
TITLE: Preparation and use of bombesin receptor antagonists for treatment of sexual dysfunction in males and females
INVENTOR(S): Gonzalez, Maria Isabel; Higginbottom, Michael; Stock, Herman Thijs; Pritchard, Martyn Clive; Pinnock, Robert Denham; Van der Graaf, Pieter Hadewijn; Naylor, Alisdair Mark; Wayman, Christopher Peter
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 105 pp., Cont.-in-part of U.S. Pat. Appl. 2002 58,606.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002169101	A1	20021114	US 2001-999284		20011115
US 2002058606	A1	20020516	US 2001-759777		20010112
ZA 2003003249	A	20040623	ZA 2003-3249		20030425
PRIORITY APPLN. INFO.:			US 1999-133355P	P	19990510
			WO 2000-GB1787	W	20000510
			US 2000-700165	A2	20001109
			US 2001-759777	A2	20010112
			GB 2001-9910	A	20010423
			GB 2001-11037	A	20010504

OTHER SOURCE(S): MARPAT 137:370356
GI



AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compds., for example PDE5 inhibitors, NEP inhibitors and lasofoxifene. Preparation of bombesin receptor antagonists consisting of α-Me

L4 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
tryptophane (e.g., I) or α-methylphenylalanine derivs. was given. In tests on sexually-dysfunctional male rats, it was concluded that I had a stimulatory effect, at the level of sexual desire, performance, and anorgasmy. In tests on sexually-dysfunctional female rats, it was concluded that I had a stimulatory effect on proceptivity, which was unaffected by repeated administration.

IT **337962-93-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of as bombesin receptor antagonists for treatment of sexual dysfunction)
RN 337962-93-3 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



IT **337962-74-0P 388630-36-2P**
RL: PUR (Purification or recovery); PREP (Preparation)
(preparation of as bombesin receptor antagonists for treatment of sexual dysfunction)
RN 337962-74-0 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 388630-36-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L4 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:391522 CAPLUS
DOCUMENT NUMBER: 136:395983
TITLE: Bombesin receptor antagonists, and combinations with other agents, for the treatment of sexual dysfunction
INVENTOR(S): Gonzalez, Maria Isabel; Stock, Herman Thijs; Pinnock, Robert Denham; Pritchard, Martyn Clive; Wayman, Christopher Peter; Van der Graaf, Pieter Hadewijn; Naylor, Alisdair Mark; Higginbottom, Michael
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002040008	A2	20020523	WO 2001-GB5018		20011114
WO 2002040008	A3	20020822			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
WO 2002040022	A1	20020523	WO 2000-GB4380		20001117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2429106	AA	20020523	CA 2001-2429106		20011114
AU 2002023802	A5	20020527	AU 2002-23802		20011114
EP 1333824	A2	20030813	EP 2001-994552		20011114
EP 1333824	B1	20050907			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001015364	A	20030923	BR 2001-15364		20011114
JP 2004522710	T2	20040729	JP 2002-542382		20011114
NZ 525415	A	20041126	NZ 2001-525415		20011114
US 2004087561	A1	20040506	US 2003-416934		20031204
PRIORITY APPLN. INFO.:			WO 2000-GB4380	W	20001117
			GB 2001-9910	A	20010423
			GB 2001-11037	A	20010504
			WO 2001-GB5018	W	20011114

OTHER SOURCE(S): MARPAT 136:395983
AB Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compds., for example phosphodiesterase V inhibitors, neutral endopeptidase

L4 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
inhibitors, and lasofoxifene. Prepn. of compds. of the invention is described.
IT **388630-36-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
RN 388630-36-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **337962-74-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)
RN 337962-74-0 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:51273 CAPLUS
DOCUMENT NUMBER: 136:96099
TITLE: Treatment of male sexual dysfunction
INVENTOR(S): Naylor, Alasdair Mark; Van der Graaf, Pieter Hadewijn; Wayman, Christopher Peter
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002003995	A2	20020117	WO 2001-IB1187	20010702
WO 2002003995	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002052370	A1	20020502	US 2001-893585	20010628
CA 2414112	AA	20020117	CA 2001-2414112	20010702
AU 2001069353	A5	20020121	AU 2001-69353	20010702
EP 1296687	A2	20030402	EP 2001-947709	20010702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004502735	T2	20040129	JP 2002-508449	20010702
NZ 522931	A	20050324	NZ 2001-522931	20010702
ZA 2003000121	A	20040121	ZA 2003-121	20030106
ZA 2003000120	A	20040126	ZA 2003-120	20030106
ZA 2003004460	A	20040624	ZA 2003-4460	20030609

PRIORITY APPLN. INFO.:

GB 2000-16684	A	20000706
GB 2000-30647	A	20001215
GB 2001-6167	A	20010313
GB 2001-8483	A	20010404
US 2000-219100P	P	20000718
GB 2001-1584	A	20010122
US 2001-274957P	P	20010312
WO 2001-IB1187	W	20010702

OTHER SOURCE(S): MARPAT 136:96099
AB The present invention relates to the use of neutral endopeptidase inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED.
IT **337962-68-2P 337962-71-7P 337962-74-0P 388630-36-2P**
RL: BMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
RN 337962-68-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 337962-71-7 CAPLUS
CN Benzenebutanoic acid, α-[[1-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]- (9CI) (CA INDEX NAME)



RN 337962-74-0 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 388630-36-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L4 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **337962-93-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)
RN 337962-93-3 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:31403 CAPLUS
DOCUMENT NUMBER: 136:102126
TITLE: Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase, and their preparation and use in the treatment of female sexual arousal disorder
INVENTOR(S): Barber, Christopher Gordon; Cook, Andrew Simon; Maw, Graham Nigel; Pryde, David Cameron; Stobie, Alan
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002513	A1	20020110	WO 2001-IB1205	20010702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002052370	A1	20020502	US 2001-893585	20010628
CA 2414881	AA	20020110	CA 2001-2414881	20010702
AU 2001067770	A5	20020114	AU 2001-67770	20010702
EP 1296938	A1	20030402	EP 2001-945557	20010702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012370	A	20030617	BR 2001-12370	20010702
JP 2004502670	T2	20040129	JP 2002-507770	20010702
NZ 522368	A	20041224	NZ 2001-522368	20010702
BG 107229	A	20030530	BG 2002-107229	20021029
NO 2002006262	A	20021227	NO 2002-6262	20021227
ZA 2003000121	A	20040121	ZA 2003-121	20030106
ZA 2003000120	A	20040126	ZA 2003-120	20030106
PRIORITY APPLN. INFO.:			GB 2000-16684 A	20000706
			GB 2001-1584 A	20010122
			US 2000-219100P P	20000718
			US 2001-274957P P	20010312
			WO 2001-IB1205 W	20010702

OTHER SOURCE(S): MARPAT 136:102126
GI



I



II



III

AB The invention provides compds. I [wherein: R1 = (un)substituted alkyl, cycloalkyl, aryl, heterocyclyl, alkoxy, amino derivative, or sulfonylamino derivative; n = 0, 1, or 2; Y = (un)substituted cycloalkyl, carbamoyl, 2-indenyl, aza- or diazainden-2-yl, 5- to 7-membered heterocyclyl, or sulfonylamino; with provisos] and their pharmaceutically acceptable salts, solvates, polymorphs, or prodrugs. I are inhibitors of neutral endopeptidase (NEP), and as such are useful for treating a variety of conditions. In particular, the compds. are useful for treatment of female sexual dysfunction, and especially female sexual arousal disorder (FSAD). Almost 60 synthetic examples and over 100 precursor prepns. are given. For instance, 1-[2-(tert-butoxycarbonyl)-4-pentenyl]cyclopentanecarboxylic acid was hydrogenated at the double bond (91%), amidated with piperonylamine using EDCI and HOBT, and deprotected with TFA, to give title compound II. The example compds. inhibited NEP in vitro with IC50 < 5000 nM, with many compds. showing at least 300-fold selectivity for NEP over angiotensin converting enzyme (ACE). An animal model of human female sexual arousal was developed, using laser doppler technol. to record small changes in vaginal and clitoral blood flow induced by pelvic nerve stimulation or vasoactive neurotransmitters in anesthetized rabbits. In this model, invention compound III significantly enhanced pelvic nerve-stimulated increases in genital blood flow at clin. relevant doses, using both i.v. and topical (vaginal) application.

IT **388630-36-2P**, (-)-(2R)-2-[[1-[[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of cyclopentyl-substituted glutaramide derivs. as neutral endopeptidase inhibitors, for treatment of female sexual arousal disorder)

RN 388630-36-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **337962-93-3P**, 2-[[1-[[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate; preparation of cyclopentyl-substituted glutaramide derivs. as neutral endopeptidase inhibitors, for treatment of female sexual arousal disorder)

RN 337962-93-3 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



IT **388630-59-9P**, (-)-(2R)-2-[[1-[[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid sodium salt
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of cyclopentyl-substituted glutaramide derivs. as neutral endopeptidase inhibitors, for treatment of female sexual arousal disorder)

RN 388630-59-9 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, monosodium salt, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● Na

IT **337962-74-0P**, (+)-(2S)-2-[[1-[[(5-Ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of cyclopentyl-substituted glutaramide derivs. as neutral endopeptidase inhibitors, for treatment of female sexual arousal disorder)

RN 337962-74-0 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **337962-68-2P**, 2-[[1-[[(1-Benzyl-6-oxo-1,6-dihydro-3-pyridinyl)amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid **337962-71-7P**, 2-[[1-[[(5-Methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]-4-phenylbutanoic acid **337962-76-2P**, 2-[[1-[[(1-Benzyl-6-oxo-1,6-dihydro-3-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid **337962-89-7P**, 2-[[1-[[(1,3-Benzodioxol-5-ylmethyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-13-5P**, 2-[[1-[[(5-Methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-14-6P**, 2-[[1-[[[(5-Methyl-1,3,4-thiadiazol-2-yl)methyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-16-8P**, 2-[[1-[[[1-Methyl-2-(2-oxopyrrolidin-1-yl)ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-19-1P**, 2-[[1-[[[2-(1H-Indol-3-yl)ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-20-4P**, 2-[[1-[[((3S)-1-Benzylpyrrolidin-3-yl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-23-7P**, 2-[[1-[[[2-(2-Oxo-1-piperidinyl)ethyl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-26-0P**,

L4 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(-)-(2R)-2-[[1-[[[5-(Cyclopropylmethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-27-1P**, (-)-(2R)-2-[[1-[[[5-(Ethoxymethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-28-2P**, 2-[[1-[(3-Pyridinylamino)carbonyl]cyclopentyl]methyl]pentanoic acid **388630-29-3P**, 2-[[1-[[(4-Butyl-2-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-32-8P**, 2-[[1-[[(5-Benzyl-3-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-38-4P**, (-)-(2R)-2-[[1-[[(1-Benzyl-6-oxo-1,6-dihydro-3-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-39-5P**, (-)-(2R)-2-[[1-[[(4-Butyl-2-pyridinyl)amino]carbonyl]cyclopentyl]methyl]pentanoic acid **388630-43-1P**, 4-Phenyl-2-[[1-[(3-pyridinylamino)carbonyl]cyclopentyl]methyl]butanoic acid **388630-48-6P**, 3-[1-[[(5-Benzyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]-2-(2-methoxyethyl)propanoic acid **388630-49-7P**, 3-[1-[[(4-Butylpyridin-2-yl)amino]carbonyl]cyclopentyl]-2-(2-methoxyethyl)propanoic acid **388630-50-0P**, 3-[1-[[(4-Phenylpyridin-2-yl)amino]carbonyl]cyclopentyl]-2-(2-methoxyethyl)propanoic acid **388630-58-8P**, 2-[[1-[[[(2,3-Dihydrobenzofuran-2-yl)methyl]amino]carbonyl]cyclopentyl]methyl]-4-methoxybutanoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of cyclopentyl-substituted glutaramide derivs. as neutral endopeptidase inhibitors, for treatment of female sexual arousal disorder)

RN 337962-68-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 337962-71-7 CAPLUS
CN Benzenebutanoic acid, α-[[1-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 388630-16-8 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1-methyl-2-(2-oxo-1-pyrrolidinyl)ethyl]amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



RN 388630-19-1 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[2-(1H-indol-3-yl)ethyl]amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



RN 388630-20-4 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 388630-23-7 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[2-(2-oxo-1-piperidinyl)ethyl]amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 337962-76-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



RN 337962-89-7 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



RN 388630-13-5 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



RN 388630-14-6 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 388630-26-0 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[5-(cyclopropylmethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 388630-27-1 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[5-(ethoxymethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 388630-28-2 CAPLUS
CN Cyclopentanepropanoic acid, α-propyl-1-[(3-pyridinylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 388630-29-3 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(4-butyl-2-pyridinyl)amino]carbonyl]-

L4 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
α-propyl- (9CI) (CA INDEX NAME)



RN 388630-32-8 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[5-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



RN 388630-38-4 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 388630-39-5 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(4-butyl-2-pyridinyl)amino]carbonyl]-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L4 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
pyridinyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 388630-58-8 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[(2,3-dihydro-2-benzofuranyl)methyl]amino]carbonyl]-α-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 388630-43-1 CAPLUS
CN Benzenebutanoic acid, α-[[1-[(3-pyridinylamino)carbonyl]cyclopentyl]methyl]- (9CI) (CA INDEX NAME)



RN 388630-48-6 CAPLUS
CN Cyclopentanepropanoic acid, α-(2-methoxyethyl)-1-[[[5-(phenylmethyl)-1,3,4-thiadiazol-2-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 388630-49-7 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(4-butyl-2-pyridinyl)amino]carbonyl]-α-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 388630-50-0 CAPLUS
CN Cyclopentanepropanoic acid, α-(2-methoxyethyl)-1-[[(4-phenyl-2-

L4 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:338075 CAPLUS
DOCUMENT NUMBER: 134:336238
TITLE: NEP (neutral endopeptidase) inhibitors for the treatment of female sexual dysfunction
INVENTOR(S): Maw, Graham Nigel; Wayman, Christopher Peter
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: Eur. Pat. Appl., 124 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097719	A1	20010509	EP 2000-309722	20001103
EP 1097719	B1	20041222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1481667	A1	20041201	EP 2004-20972	20001103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI, CY, TR				
AT 285249	E	20050115	AT 2000-309722	20001103
PT 1097719	T	20050429	PT 2000-309722	20001103
ES 2233297	T3	20050616	ES 2000-309722	20001103
ZA 2000006374	A	20020506	ZA 2000-6374	20001106
ZA 2000006375	A	20020506	ZA 2000-6375	20001106
ZA 2000006376	A	20020506	ZA 2000-6376	20001106
ZA 2000006378	A	20020506	ZA 2000-6378	20001106
AU 781186	B2	20050512	AU 2000-71411	20001106
AU 781400	B2	20050519	AU 2000-71407	20001106
AU 781403	B2	20050519	AU 2000-71408	20001106
CA 2323183	AA	20010508	CA 2000-2323183	20001107
CA 2323191	AA	20010508	CA 2000-2323191	20001107
CA 2323464	AA	20010508	CA 2000-2323464	20001107
CA 2324484	AA	20010508	CA 2000-2324484	20001107
NO 2000005618	A	20010509	NO 2000-5618	20001107
NO 2000005661	A	20010509	NO 2000-5661	20001107
NO 2000005662	A	20010509	NO 2000-5662	20001107
CN 1320426	A	20011107	CN 2000-137665	20001107
CN 1322526	A	20011121	CN 2000-137671	20001107
CN 1328824	A	20020102	CN 2000-137670	20001107
NZ 508006	A	20020628	NZ 2000-508006	20001107
NZ 508007	A	20020628	NZ 2000-508007	20001107
NZ 508011	A	20020628	NZ 2000-508011	20001107
NZ 508012	A	20020628	NZ 2000-508012	20001107
BR 2000005266	A	20030408	BR 2000-5266	20001107
JP 2001206855	A2	20010731	JP 2000-339905	20001108
JP 2001213802	A2	20010807	JP 2000-339853	20001108
JP 2001247478	A2	20010911	JP 2000-339949	20001108
JP 2001247479	A2	20010911	JP 2000-339957	20001108
BR 2000005276	A	20030408	BR 2000-5276	20001108
BR 2000005299	A	20030415	BR 2000-5299	20001108
US 6734186	B1	20040511	US 2000-708392	20001108
US 2004254153	A1	20041216	US 2003-686390	20031015
US 2005020547	A1	20050127	US 2003-686282	20031015
US 2005070499	A1	20050331	US 2003-686349	20031015
JP 2005013237	A2	20050120	JP 2004-268608	20040915
JP 2005021167	A2	20050127	JP 2004-267669	20040915

L4 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

JP 2005043377	A2	20050217	JP 2004-269807		20040916
JP 2005070055	A2	20050317	JP 2004-269732		20040916
PRIORITY APPLN. INFO.:			GB 1999-26437	A	19991108
			GB 2000-4021	A	20000218
			GB 2000-13001	A	20000526
			GB 2000-16563	A	20000705
			GB 2000-17141	A	20000712
			US 2000-175161P	P	20000107
			US 2000-192962P	P	20000329
			US 2000-217479P	P	20000711
			US 2000-221014P	P	20000727
			US 2000-221093P	P	20000727
			EP 2000-309722	A3	20001103
			JP 2000-339853	A3	20001108
			JP 2000-339905	A3	20001108
			JP 2000-339949	A3	20001108
			JP 2000-339957	A3	20001108
			US 2000-708392	A3	20001108

AB A method of treating a female suffering from female sexual dysfunction, in particular female sexual arousal dysfunction, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia, wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. The agent is an inhibitor of NEP (neutral endopeptidase; EC 3.4.24.11).

IT **337962-68-2P 337962-71-7P 337962-74-0P**
337962-76-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neutral endopeptidase inhibitors for treatment of female sexual dysfunction)

RN 337962-68-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 337962-71-7 CAPLUS
CN Benzenebutanoic acid, α-[[1-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 337962-74-0 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 337962-76-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



IT **337962-89-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(neutral endopeptidase inhibitors for treatment of female sexual dysfunction)

RN 337962-89-7 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2001:338074 CAPLUS
DOCUMENT NUMBER:	134:336237
TITLE:	Neuropeptide Y (NPY) antagonists for the treatment of female sexual dysfunction
INVENTOR(S):	Maw, Graham Nigel; Wayman, Christopher Peter
PATENT ASSIGNEE(S):	Pfizer Limited, UK; Pfizer Inc.
SOURCE:	Eur. Pat. Appl., 165 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	5
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097718	A1	20010509	EP 2000-309720	20001103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 285249	E	20050115	AT 2000-309722	20001103
PT 1097719	T	20050429	PT 2000-309722	20001103
ES 2233297	T3	20050616	ES 2000-309722	20001103
ZA 2000006374	A	20020506	ZA 2000-6374	20001106
ZA 2000006375	A	20020506	ZA 2000-6375	20001106
ZA 2000006376	A	20020506	ZA 2000-6376	20001106
ZA 2000006378	A	20020506	ZA 2000-6378	20001106
AU 781186	B2	20050512	AU 2000-71411	20001106
AU 781400	B2	20050519	AU 2000-71407	20001106
AU 781403	B2	20050519	AU 2000-71408	20001106
CA 2323183	AA	20010508	CA 2000-2323183	20001107
CA 2323191	AA	20010508	CA 2000-2323191	20001107
CA 2323464	AA	20010508	CA 2000-2323464	20001107
CA 2324484	AA	20010508	CA 2000-2324484	20001107
NO 2000005618	A	20010509	NO 2000-5618	20001107
NO 2000005661	A	20010509	NO 2000-5661	20001107
NO 2000005662	A	20010509	NO 2000-5662	20001107
CN 1320426	A	20011107	CN 2000-137665	20001107
CN 1322526	A	20011121	CN 2000-137671	20001107
CN 1328824	A	20020102	CN 2000-137670	20001107
NZ 508006	A	20020628	NZ 2000-508006	20001107
NZ 508007	A	20020628	NZ 2000-508007	20001107
NZ 508011	A	20020628	NZ 2000-508011	20001107
NZ 508012	A	20020628	NZ 2000-508012	20001107
BR 2000005266	A	20030408	BR 2000-5266	20001107
JP 2001206855	A2	20010731	JP 2000-339905	20001108
JP 2001213802	A2	20010807	JP 2000-339853	20001108
JP 2001247478	A2	20010911	JP 2000-339949	20001108
JP 2001247479	A2	20010911	JP 2000-339957	20001108
BR 2000005276	A	20030408	BR 2000-5276	20001108
BR 2000005299	A	20030415	BR 2000-5299	20001108
US 6734186	B1	20040511	US 2000-708392	20001108
US 2004254153	A1	20041216	US 2003-686390	20031015
US 2005020547	A1	20050127	US 2003-686282	20031015
US 2005070499	A1	20050331	US 2003-686349	20031015
JP 2005013237	A2	20050120	JP 2004-268608	20040915
JP 2005021167	A2	20050127	JP 2004-267669	20040915
JP 2005043377	A2	20050217	JP 2004-269807	20040916
JP 2005070055	A2	20050317	JP 2004-269732	20040916
PRIORITY APPLN. INFO.:			GB 1999-26437	A 19991108
			GB 2000-4021	A 20000218

L4 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

GB 2000-13001	A	20000526
GB 2000-16563	A	20000705
GB 2000-17141	A	20000712
US 2000-175161P	P	20000107
US 2000-192962P	P	20000329
US 2000-217479P	P	20000711
US 2000-221014P	P	20000727
US 2000-221093P	P	20000727
JP 2000-339853	A3	20001108
JP 2000-339905	A3	20001108
JP 2000-339949	A3	20001108
JP 2000-339957	A3	20001108
US 2000-708392	A3	20001108

AB A method of treating a female suffering from female sexual dysfunction, in particular female sexual arousal dysfunction, is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia, wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. The agent is an antagonist of NPY. Preparation of neutral endopeptidase inhibitors, also use for treating the above disorders, is also described.

IT **337962-68-2P 337962-71-7P 337962-74-0P 337962-76-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neuropeptide Y antagonists for the treatment of female sexual dysfunction)

RN 337962-68-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 337962-71-7 CAPLUS
CN Benzenebutanoic acid, α-[[1-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 337962-74-0 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 337962-76-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



IT **337962-89-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(neuropeptide Y antagonists for the treatment of female sexual dysfunction)

RN 337962-89-7 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2001:338068 CAPLUS
DOCUMENT NUMBER:	134:348237
TITLE:	Treatment of female sexual arousal dysfunction
INVENTOR(S):	Maw, Graham Nigel; Wayman, Christopher Peter
PATENT ASSIGNEE(S):	Pfizer Limited, UK; Pfizer Inc.
SOURCE:	Eur. Pat. Appl., 135 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	5
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097707	A1	20010509	EP 2000-309719	20001103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 285249	E	20050115	AT 2000-309722	20001103
PT 1097719	T	20050429	PT 2000-309722	20001103
ES 2233297	T3	20050616	ES 2000-309722	20001103
ZA 2000006374	A	20020506	ZA 2000-6374	20001106
ZA 2000006375	A	20020506	ZA 2000-6375	20001106
ZA 2000006376	A	20020506	ZA 2000-6376	20001106
ZA 2000006378	A	20020506	ZA 2000-6378	20001106
AU 781186	B2	20050512	AU 2000-71411	20001106
AU 781400	B2	20050519	AU 2000-71407	20001106
AU 781403	B2	20050519	AU 2000-71408	20001106
CA 2323183	AA	20010508	CA 2000-2323183	20001107
CA 2323191	AA	20010508	CA 2000-2323191	20001107
CA 2323464	AA	20010508	CA 2000-2323464	20001107
CA 2324484	AA	20010508	CA 2000-2324484	20001107
NO 2000005618	A	20010509	NO 2000-5618	20001107
NO 2000005661	A	20010509	NO 2000-5661	20001107
NO 2000005662	A	20010509	NO 2000-5662	20001107
CN 1320426	A	20011107	CN 2000-137665	20001107
CN 1322526	A	20011121	CN 2000-137671	20001107
CN 1328824	A	20020102	CN 2000-137670	20001107
NZ 508006	A	20020628	NZ 2000-508006	20001107
NZ 508007	A	20020628	NZ 2000-508007	20001107
NZ 508011	A	20020628	NZ 2000-508011	20001107
NZ 508012	A	20020628	NZ 2000-508012	20001107
BR 2000005266	A	20030408	BR 2000-5266	20001107
JP 2001206855	A2	20010731	JP 2000-339905	20001108
JP 2001213802	A2	20010807	JP 2000-339853	20001108
JP 2001247478	A2	20010911	JP 2000-339949	20001108
JP 2001247479	A2	20010911	JP 2000-339957	20001108
BR 2000005276	A	20030408	BR 2000-5276	20001108
BR 2000005299	A	20030415	BR 2000-5299	20001108
US 6734186	B1	20040511	US 2000-708392	20001108
US 2004254153	A1	20041216	US 2003-686390	20031015
US 2005020547	A1	20050127	US 2003-686282	20031015
US 2005070499	A1	20050331	US 2003-686349	20031015
JP 2005013237	A2	20050120	JP 2004-268608	20040915
JP 2005021167	A2	20050127	JP 2004-267669	20040915
JP 2005043377	A2	20050217	JP 2004-269807	20040916
JP 2005070055	A2	20050317	JP 2004-269732	20040916

PRIORITY APPLN. INFO.:	GB 1999-26437	A 19991108
	GB 2000-4021	A 20000218
	GB 2000-13001	A 20000526

L4 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

GB 2000-16563	A	20000705
GB 2000-17141	A	20000712
US 2000-175161P	P	20000107
US 2000-192962P	P	20000329
US 2000-217479P	P	20000711
US 2000-221014P	P	20000727
US 2000-221093P	P	20000727
JP 2000-339853	A3	20001108
JP 2000-339905	A3	20001108
JP 2000-339949	A3	20001108
JP 2000-339957	A3	20001108
US 2000-708392	A3	20001108

AB A method of treating a female suffering from female sexual dysfunction (FSD), in particular female sexual arousal dysfunction (FSAD), is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient.

IT **337962-68-2P 337962-71-7P 337962-74-0P 337962-76-2P 337962-89-7P 337962-93-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(treatment of female sexual arousal dysfunction)

RN 337962-68-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 337962-71-7 CAPLUS
CN Benzenebutanoic acid, α-[[1-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]- (9CI) (CA INDEX NAME)



RN 337962-74-0 CAPLUS

L4 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Cyclopentanepropanoic acid, 1-[[[5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 337962-76-2 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



RN 337962-89-7 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



RN 337962-93-3 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:338067 CAPLUS
DOCUMENT NUMBER: 134:348236
TITLE: Phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction
INVENTOR(S): Maw, Graham Nigel; Wayman, Christopher Peter
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: Eur. Pat. Appl., 129 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097706	A1	20010509	EP 2000-309718	20001103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 285249	E	20050115	AT 2000-309722	20001103
PT 1097719	T	20050429	PT 2000-309722	20001103
ES 2233297	T3	20050616	ES 2000-309722	20001103
ZA 2000006374	A	20020506	ZA 2000-6374	20001106
ZA 2000006375	A	20020506	ZA 2000-6375	20001106
ZA 2000006376	A	20020506	ZA 2000-6376	20001106
ZA 2000006378	A	20020506	ZA 2000-6378	20001106
AU 781186	B2	20050512	AU 2000-71411	20001106
AU 781400	B2	20050519	AU 2000-71407	20001106
AU 781403	B2	20050519	AU 2000-71408	20001106
CA 2323183	AA	20010508	CA 2000-2323183	20001107
CA 2323191	AA	20010508	CA 2000-2323191	20001107
CA 2323464	AA	20010508	CA 2000-2323464	20001107
CA 2324484	AA	20010508	CA 2000-2324484	20001107
NO 2000005618	A	20010509	NO 2000-5618	20001107
NO 2000005661	A	20010509	NO 2000-5661	20001107
NO 2000005662	A	20010509	NO 2000-5662	20001107
CN 1320426	A	20011107	CN 2000-137665	20001107
CN 1322526	A	20011121	CN 2000-137671	20001107
CN 1328824	A	20020102	CN 2000-137670	20001107
NZ 508006	A	20020628	NZ 2000-508006	20001107
NZ 508007	A	20020628	NZ 2000-508007	20001107
NZ 508011	A	20020628	NZ 2000-508011	20001107
NZ 508012	A	20020628	NZ 2000-508012	20001107
BR 2000005266	A	20030408	BR 2000-5266	20001107
JP 2001206855	A2	20010731	JP 2000-339905	20001108
JP 2001213802	A2	20010807	JP 2000-339853	20001108
JP 2001247478	A2	20010911	JP 2000-339949	20001108
JP 2001247479	A2	20010911	JP 2000-339957	20001108
BR 2000005276	A	20030408	BR 2000-5276	20001108
BR 2000005299	A	20030415	BR 2000-5299	20001108
US 6734186	B1	20040511	US 2000-708392	20001108
US 2004254153	A1	20041216	US 2003-686390	20031015
US 2005020547	A1	20050127	US 2003-686282	20031015
US 2005070499	A1	20050331	US 2003-686349	20031015
JP 2005013237	A2	20050120	JP 2004-268608	20040915
JP 2005021167	A2	20050127	JP 2004-267669	20040915
JP 2005043377	A2	20050217	JP 2004-269807	20040916
JP 2005070055	A2	20050317	JP 2004-269732	20040916
PRIORITY APPLN. INFO.:			GB 1999-26437 A	19991108
			GB 2000-4021 A	20000218

L4 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

GB 2000-13001	A	20000526
GB 2000-16563	A	20000705
GB 2000-17141	A	20000712
US 2000-175161P	P	20000107
US 2000-192962P	P	20000329
US 2000-217479P	P	20000711
US 2000-221014P	P	20000727
US 2000-221093P	P	20000727
JP 2000-339853	A3	20001108
JP 2000-339905	A3	20001108
JP 2000-339949	A3	20001108
JP 2000-339957	A3	20001108
US 2000-708392	A3	20001108

AB A method of treating a female suffering from female sexual dysfunction (FSD), in particular female sexual arousal dysfunction (FSAD), is described. The method comprises delivering to the female an agent that is capable of potentiating cAMP in the sexual genitalia; wherein the agent is in an amount to cause potentiation of cAMP in the sexual genitalia of the female. The agent may be admixed with a pharmaceutically acceptable carrier, diluent or excipient. Said agent is a phosphodiesterase (PDE) inhibitor wherein said PDE is a cAMP hydrolyzing PDE (and optionally cGMP hydroxyzing).

IT **337962-68-2P 337962-71-7P 337962-74-0P**
337962-76-2P 337962-89-7P 337962-93-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phosphodiesterase inhibitors for the treatment of female sexual arousal dysfunction)

RN 337962-68-2 CAPLUS

CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 337962-71-7 CAPLUS

CN Benzenebutanoic acid, α-[[1-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]cyclopentyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 337962-74-0 CAPLUS

CN Cyclopentanepropanoic acid, 1-[[(5-ethyl-1,3,4-thiadiazol-2-yl)amino]carbonyl]-α-propyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 337962-76-2 CAPLUS

CN Cyclopentanepropanoic acid, 1-[[[1,6-dihydro-6-oxo-1-(phenylmethyl)-3-pyridinyl]amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



RN 337962-89-7 CAPLUS

CN Cyclopentanepropanoic acid, 1-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-α-propyl- (9CI) (CA INDEX NAME)



RN 337962-93-3 CAPLUS

L4 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:50486 CAPLUS
DOCUMENT NUMBER: 134:105881
TITLE: Pharmaceuticals with protective effects against oxidative-toxic substances, particularly against cardiotoxic substances
INVENTOR(S): Rozsa, Zsuzsanna; Papp, Julius G.; Thormahlen, Dirk; Waldeck, Harald
PATENT ASSIGNEE(S): Solvay Pharmaceuticals G.m.b.H., Germany
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001003699	A1	20010118	WO 2000-EP6525	20000710
W: AU, BR, CA, CN, CZ, DZ, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PL, RU, SK, TR, UA, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19932555	A1	20010118	DE 1999-19932555	19990713
CA 2377904	AA	20010118	CA 2000-2377904	20000710
BR 2000012442	A	20020402	BR 2000-12442 \	20000710
EP 1200095	A1	20020502	EP 2000-947960	20000710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
TR 200200053	T2	20020521	TR 2002-200200053	20000710
JP 2003504336	T2	20030204	JP 2001-508979	20000710
NZ 517130	A	20041029	NZ 2000-517130	20000710
AU 782733	B2	20050825	AU 2000-61572	20000710
NO 2002000132	A	20020312	NO 2002-132	20020111
ZA 2002000265	A	20030113	ZA 2002-265	20020111
US 2003040512	A1	20030227	US 2002-43268	20020114
US 6906059	B2	20050614		

PRIORITY APPLN. INFO.: DE 1999-19932555 A 19990713
WO 2000-EP6525 W 20000710

OTHER SOURCE(S): MARPAT 134:105881

AB The invention relates to the utilization of benzazepine-N-acetic acid derivs. which contain an oxo group in addition to the nitrogen atom in the α-position and which are substituted in the third position by a 1-(carboxyalkyl)cyclopentylcarbonylamino group and to their salts and biolabile esters for the prophylaxis and/or treatment of heart damages caused by cardiotoxic doses of drugs or chems. in large mammals and particularly humans. beings. The invention particularly relates to the prophylaxis and/or treatment of heart damages, especially myocardial damages,
which may occur during cytostatic chemotherapy. The invention further relates to the utilization of these benzazepine-N-acetic acid derivs. for adjuvant treatment in therapy in which drugs, which have undesirable oxidative-toxic side effects, are used. The invention addnl. relates to the production of drugs suitable for the prophylaxis and/or treatment or adjuvant treatment. Thus, tablets were prepared from (3S,2'R)-3-(1-[2'-(ethoxycarbonyl)-4'-phenylbutyl]cyclopentane-1-carbonylamino)-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid 20, corn starch 60, lactose 135, and gelatin (10% solution) 6 mg/tablet.

IT **182560-86-7 182560-97-0 182821-29-0**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L4 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(pharmaceuticals with protective effects against cardiotoxic substances)
RN 182560-86-7 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 182560-97-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, α-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 182821-29-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-carboxy-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:574119 CAPLUS
DOCUMENT NUMBER: 133:172184
TITLE: Medicament for treatment of high blood pressure
INVENTOR(S): Wilkins, Martin R.; Thormaehlen, Dirk; Waldeck, Harald
PATENT ASSIGNEE(S): Solvay Pharmaceuticals G.m.b.H., Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19906310	A1	20000817	DE 1999-19906310	19990216
TW 221770	B1	20041011	TW 2000-89101041	20000121
CA 2362273	AA	20000824	CA 2000-2362273	20000210
WO 2000048601	A1	20000824	WO 2000-EP1068	20000210
W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PL, RU, SK, TR, UA, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
NZ 514058	A	20010928	NZ 2000-514058	20000210
BR 2000008260	A	20011106	BR 2000-8260	20000210
EP 1154777	A1	20011121	EP 2000-903681	20000210
EP 1154777	B1	20050511		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 200102386	T2	20020121	TR 2001-200102386	20000210
JP 2002537258	T2	20021105	JP 2000-599393	20000210
AU 773240	B2	20040520	AU 2000-25476	20000210
AT 295174	E	20050515	AT 2000-903681	20000210
PT 1154777	T	20050729	PT 2000-903681	20000210
ZA 2001005828	A	20020715	ZA 2001-5828	20010716
NO 2001003958	A	20011015	NO 2001-3958	20010815
US 2002052361	A1	20020502	US 2001-930186	20010816
US 6482820	B2	20021119		

PRIORITY APPLN. INFO.: DE 1999-19906310 A 19990216
WO 2000-EP1068 W 20000210
OTHER SOURCE(S): MARPAT 133:172184
GI



AB Benzazepine-N-acetic acid derivs. I [R1 = (substituted) phenylalkyl,

L4 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
naphthylalkyl; R2; R3 = H, biolabile ester-forming group] are useful for treatment of high blood pressure regardless of etiol., esp. certain forms of secondary hypertension assocd. with noncardiac disorders. Thus, rats with hypoxia-induced pulmonary hypertension, treated with (3S,2'R)-3-[1-(2-carboxy-4-phenylbutyl)cyclopentane-1-carbonylamino]-2,3,4,5-tetrahydro-2-oxo-(1H)-1-benzazepine-1-acetic acid (II) (40 mg/kg i.p./day by osmotic minipump), showed a redn. in pulmonary arterial pressure with no effect on the systemic blood pressure. A sterile injection soln. contained II 10, Na2HPO4.7H2O 43.24, NaH2PO4.2H2O 7.72, NaCl 30.0, and H2O 4948.0 mg.
IT 182821-29-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicament for treatment of high blood pressure)
RN 182821-29-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-carboxy-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:545910 CAPLUS
DOCUMENT NUMBER: 134:159784
TITLE: A novel method of aligning molecules by local surface shape similarity
AUTHOR(S): Cosgrove, D. A.; Bayada, D. M.; Johnson, A. P.
CORPORATE SOURCE: AstraZeneca, Macclesfield, SK10 4TG, UK
SOURCE: Journal of Computer-Aided Molecular Design (2000), 14(6), 573-591
CODEN: JCADEQ; ISSN: 0920-654X
PUBLISHER: Kluwer Academic Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A novel shape-based method has been developed for overlaying a series of mol. surfaces into a common reference frame. The surfaces are represented by a set of circular patches of approx. constant curvature. Two mols. are overlaid using a clique-detection algorithm to find a set of patches in the two surfaces that correspond, and overlaying the mols. so that the similar patches on the two surfaces are coincident. The method is thus able to detect areas of local, rather than global, similarity. A consensus overlay for a group of mols. is performed by examining the scores of all pairwise overlays and performing a set of overlays with the highest scores. The utility of the method has been examined by comparing the overlaid and exptl. configurations of 4 sets of mols. for which there are x-ray crystal structures of the mols. bound to a protein active site. Results for the overlays are generally encouraging. Of particular note is the correct prediction of the "reverse orientation" for ligands binding to human rhinovirus coat protein HRV14.
IT 129980-23-0
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(novel method of aligning mols. by local surface shape similarity)
RN 129980-23-0 CAPLUS
CN L-Tryptophan, N-[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:196303 CAPLUS
DOCUMENT NUMBER: 128:239479
TITLE: Benzazepineacetic acid derivatives promoting gastrointestinal blood circulation
INVENTOR(S): Rozsa, Susanna; Papp, Julius Gy.; Thormaehlen, Dirk; Waldeck, Harald
PATENT ASSIGNEE(S): Solvay Pharmaceuticals G.m.b.H., Germany
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19638020	A1	19980319	DE 1996-19638020	19960918
EP 830863	A1	19980325	EP 1997-115603	19970909
EP 830863	B1	20000510		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
ES 2145545	T3	20000701	ES 1997-115603	19970909
US 5783573	A	19980721	US 1997-929114	19970915
JP 10101565	A2	19980421	JP 1997-251928	19970917

PRIORITY APPLN. INFO.: DE 1996-19638020 A 19960918
OTHER SOURCE(S): MARPAT 128:239479
GI



AB Benzazepineacetic acid derivs. I [R1 = (substituted) phenylalkyl, naphthylalkyl; R2, R3 = H, group forming a biol. labile ester] and their salts are useful in pharmaceutical compns. for treatment and/or prophylaxis of disorders in the gastrointestinal (mesenteric) circulation of various etiol. in humans and large mammals. Thus, in rats with streptozotocin-induced diabetes, the mesenteric arterial blood pressure was 9 mL/min; this was increased to 14 mL/min by treatment with I (substituents not specified) at 30 mg/kg/day orally for 8 wk. Tablets were prepared containing (3S,2R)-I (R1 = PhCH2CH2, R2 = Et, R3 = H) (II) 20, corn starch 60, lactose 135, and gelatin 6 mg. II was prepared from di-Et malonate and phenethyl bromide via 2-carboxy-4-phenylbutyric acid and Et α-(2-phenethyl)acrylate, reaction with cyclopentanecarboxylic acid, resolution with L(-)-α-methylbenzylamine, condensation with tert-Bu 3-amino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetate, etc.

IT **182560-86-7P 182560-97-0P 182821-33-6P**
204781-61-3P 204781-62-4P 204781-63-5P
204781-64-6P 204781-65-7P 204781-69-1P

L4 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 204781-61-3 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204781-62-4 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(1-naphthalenyl)butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204781-63-5 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-3-phenylpropyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
204781-70-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzazepineacetic acid derivs. promoting gastrointestinal blood circulation)
RN 182560-86-7 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 182560-97-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, α-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 182821-33-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-carboxy-4-(1-naphthalenyl)butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 204781-64-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-3-phenylpropyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204781-65-7 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-3-(4-methylphenyl)propyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204781-69-1 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, disodium salt, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●2 Na

RN 204781-70-4 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-3-(1-naphthalenyl)propyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:646474 CAPLUS
DOCUMENT NUMBER: 125:301029
TITLE: Preparation of 3-[[[(1-carboxyalkyl)cyclopentyl]carbonylamino]benzazepin-1-acetates and analogs as neutral endopeptidase inhibitors
INVENTOR(S): Waldeck, Harald; Hoeltje, Dagmar; Messinger, Josef; Antel, Jochen; Wurl, Michael; Thormaehlen, Dirk
PATENT ASSIGNEE(S): Kali-Chemie Pharma Gmbh, Germany
SOURCE: Eur. Pat. Appl., 35 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 733642	A1	19960925	EP 1996-104265	19960318
EP 733642	B1	20001129		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 19510566	A1	19960926	DE 1995-19510566	19950323
ZA 9601243	A	19960827	ZA 1996-1243	19960216
IL 117265	A1	20000716	IL 1996-117265	19960226
SK 281079	B6	20001107	SK 1996-354	19960315
AT 197801	E	20001215	AT 1996-104265	19960318
ES 2152444	T3	20010201	ES 1996-104265	19960318
PT 733642	T	20010330	PT 1996-104265	19960318
CN 1147506	A	19970416	CN 1996-104257	19960320
CN 1059436	B	20001213		
RU 2159768	C2	20001127	RU 1996-105383	19960320
CA 2172354	AA	19960924	CA 1996-2172354	19960321
CA 2172354	C	20021008		
AU 9648210	A1	19961003	AU 1996-48210	19960321
AU 701271	B2	19990121		
NO 9601181	A	19960924	NO 1996-1181	19960322
JP 08269011	A2	19961015	JP 1996-66703	19960322
US 5677297	A	19971014	US 1996-620213	19960322
CZ 289245	B6	20011212	CZ 1996-863	19960322
PL 184336	B1	20021031	PL 1996-313433	19960322
GR 3035410	T3	20010531	GR 2001-400240	20010214

PRIORITY APPLN. INFO.: DE 1995-19510566 A 19950323
OTHER SOURCE(S): MARPAT 125:301029
GI

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

AB Title compds. (I; R1 = alkoxyalkoxyalkyl, phenylalkyl, phenoxyalkyl, etc.; R2,R3 = H or halo; R4,R5 = H, metabolism labile ester residue; Z = CH2, O, S) were prepared Thus, tert-Bu 3-amino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetate was amidated by 1-(2-ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxylic acid (preparation each given) to give I (R1 = CH2CH2Ph, R2 = R3 = H, R4 = Et, R5 = CMe3, Z = CH2). Data for in vitro and in vivo biol. activity of I were given.

IT 182560-86-7P 182560-90-3P 182560-91-4P
182560-95-8P 182560-97-0P 182561-00-8P
182561-01-9P 182561-02-0P 182561-03-1P
182561-04-2P 182561-05-3P 182561-06-4P
182561-07-5P 182561-08-6P 182561-13-3P
182561-29-1P 182561-30-4P 182561-31-5P
182561-32-6P 182561-33-7P 182561-34-8P
182561-35-9P 182561-40-6P 182704-04-7P
182821-29-0P 182821-30-3P 182821-31-4P
182821-32-5P 182821-33-6P 182821-36-9P
182821-37-0P 182824-17-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-[[(1-carboxyalkyl)cyclopentyl]carbonylamino]benzazepin-1-acetates and analogs as neutral endopeptidase inhibitors)

RN 182560-86-7 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo- (9CI) (CA INDEX NAME)



RN 182560-90-3 CAPLUS
CN 1,5-Benzoxazepine-5(2H)-acetic acid, 3-[[[1-[2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentyl]carbonyl]amino]-3,4-dihydro-4-oxo-,

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
α-(phenylmethyl) ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 182560-91-4 CAPLUS
CN 1,5-Benzoxazepine-5(2H)-acetic acid, 3-[[[1-[2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentyl]carbonyl]amino]-3,4-dihydro-4-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 182560-95-8 CAPLUS
CN 1,5-Benzothiazepine-5(2H)-acetic acid, 3-[[[1-[2-carboxy-5-(3,4-dimethoxyphenyl)pentyl]cyclopentyl]carbonyl]amino]-3,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 182560-97-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, α-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 182561-00-8 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 182561-01-9 CAPLUS

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(4-fluorophenoxy)butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 182561-05-3 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-3-phenylpropyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 182561-06-4 CAPLUS
CN 1,5-Benzoxazepine-5(2H)-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-3,4-dihydro-4-oxo-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182561-07-5 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-3-(4-methylphenyl)propyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 182561-02-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(1-naphthalenyl)butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 182561-03-1 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-5-phenoxypentyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 182561-04-2 CAPLUS

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 182561-08-6 CAPLUS
CN 1,5-Benzothiazepine-5(2H)-acetic acid, 3-[[[1-[2-carboxy-5-(4-methoxyphenyl)pentyl]cyclopentyl]carbonyl]amino]-3,4-dihydro-4-oxo-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182561-13-3 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-3-(1-naphthalenyl)propyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 182561-29-1 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 182561-30-4 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 182561-31-5 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(1-naphthalenyl)butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 182561-32-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-5-phenoxypentyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 182561-40-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-3-(1-naphthalenyl)propyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 182704-04-7 CAPLUS
CN 1,5-Benzothiazepine-5(2H)-acetic acid, 3-[[[1-[2-carboxy-4-(4-fluorophenoxy)butyl]cyclopentyl]carbonyl]amino]-ar,ar-dichloro-3,4-dihydro-4-oxo-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 182561-33-7 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-4-(4-fluorophenoxy)butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 182561-34-8 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-3-phenylpropyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 182561-35-9 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-carboxy-3-(4-methylphenyl)propyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

2 (D1-Cl)

RN 182821-29-0 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-carboxy-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182821-30-3 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2S)-2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 182821-31-4 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182821-32-5 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-3-phenylpropyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182821-33-6 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-[(2R)-2-carboxy-4-(1-naphthalenyl)butyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

2 (D1—Cl)

L4 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 182821-36-9 CAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[[1-(2-carboxy-3-phenylpropyl)cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182821-37-0 CAPLUS
CN 1,5-Benzothiazepine-5(2H)-acetic acid, 3-[[[1-[2-carboxy-5-(4-methoxyphenyl)pentyl]cyclopentyl]carbonyl]amino]-3,4-dihydro-4-oxo-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 182824-17-5 CAPLUS
CN 1,5-Benzothiazepine-5(2H)-acetic acid, 3-[[[1-[2-carboxy-4-(4-fluorophenoxy)butyl]cyclopentyl]carbonyl]amino]-ar,ar-dichloro-3,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:494199 CAPLUS
DOCUMENT NUMBER: 125:184878
TITLE: Three-Dimensional Models of ACE and NEP Inhibitors and Their Use in the Design of Potent Dual ACE/NEP Inhibitors
AUTHOR(S): Bohacek, Regine; De Lombaert, Stephane; McMartin, Colin; Priestle, John; Gruetter, Markus
CORPORATE SOURCE: Pharmaceuticals Division, Ciba-Geigy Corporation, Summit, NJ, 07901, USA
SOURCE: Journal of the American Chemical Society (1996), 118(35), 8231-8249
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A composite template for angiotensin converting enzyme (ACE, EC 2.4.15.1) inhibitors and a hypothetical model of the active site of neutral endopeptidase (NEP, EC 3.4.24.11) have been constructed and used to guide the design of dual ACE/NEP inhibitors. For the ACE template, a new computer program was used to flexibly superimpose potent, conformationally restricted ACE inhibitors. This program, which only considers the structures of the ligands, generated three possible templates. It was possible to evaluate the plausibility of these templates because new x-ray data is extending the authors knowledge of the binding of ligands to zinc metalloproteases. The authors have found that the available x-ray structures of inhibitors complexed to different zinc metalloproteases share certain conformational features. In each complex, the regions between the catalytic zinc and the P1' side chain were found to have almost the same geometry. This geometry appears to be dictated by the mechanism of catalysis. Only one of the templates displays this geometry and is, therefore, proposed as a pharmacophore for ACE. To simulate NEP, the authors used the crystal structure of the active site of thermolysin (EC 3.4.24.4). These models of ACE and NEP predict that the conformation an inhibitor must adopt to bind to ACE differs from that required for binding to NEP. The authors have designed inhibitors in which conformationally restricted sections are linked by a flexible hinge, allowing the mols. to adapt to the conformation required by each enzyme. One of these inhibitors, a tricyclic α-thiol, CGS 28106 (I), was found to inhibit both ACE and NEP with an IC50 of 40 and 49 nM, resp. The models predict that I binds to the S1', S2', and S3' subsites of NEP and thermolysin and to the S1, S1', and S2' subsites of ACE. The predicted mode of binding of I to thermolysin was exptl. verified by the determination of the x-ray crystal structure of the thermolysin/I complex. This is the first reported three-dimensional structure of an α-thiol bound to a zinc metalloprotease. Except for a single NEP inhibitor, the models the authors propose for ACE and NEP are able to differentiate between active and inactive compds. reported in the present as well as other studies of dual ACE/NEP inhibition.

IT 129980-23-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(three-dimensional models of angiotensin-converting enzyme and neutral endopeptidase inhibitors using inhibitor template and thermolysin and its use in design of potent dual inhibitors)

RN 129980-23-0 CAPLUS
CN L-Tryptophan, N-[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.



L4 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:51312 CAPLUS
DOCUMENT NUMBER: 124:164308
TITLE: Hydration in drug design. 2. Influence of local site surface shape on water binding
AUTHOR(S): Poornima, C. S.; Dean, P. M.
CORPORATE SOURCE: Dep. Pharmacology, Univ. Cambridge, Cambridge, CB2 1QJ, UK
SOURCE: Journal of Computer-Aided Molecular Design (1995), 9(6), 513-20
CODEN: JCADEQ; ISSN: 0920-654X
PUBLISHER: ESCOM
DOCUMENT TYPE: Journal
LANGUAGE: English
AB If water mols. are strongly bound at a protein-ligand interface, they are unlikely to be displaced during ligand binding. Such water mols. can change the shape of the ligand binding site and thus affect strategies for drug design. To understand the nature of water binding, and factors influencing it, water mols. at the ligand binding sites of 26 high-resolution protein-ligand complexes have been examined here. Water mols. bound in deep grooves and cavities between the protein and the ligand are located in the indentations on the protein-site surface, but not in the indentations on the ligand surface. The majority of the water mols. bound in deep indentations on the protein-site surface make multiple polar contacts with the protein surface. This may indicate a strong binding of water mols. in deep indentations on protein-site surfaces. The local shape of the site surface may influence the binding of water mols. that mediate protein-ligand interactions.
IT 129980-23-0
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(hydration in drug design - influence of local site surface shape on water binding)
RN 129980-23-0 CAPLUS
CN L-Tryptophan, N-[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:268877 CAPLUS
DOCUMENT NUMBER: 122:46490
TITLE: Tryptophans as inhibitors for formation of endothelin
INVENTOR(S): Tanaka, Hiroko; Nakada, Tomohisa; Endo, Noriaki
PATENT ASSIGNEE(S): Teijin Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06279284	A2	19941004	JP 1993-95164	19930331
PRIORITY APPLN. INFO.:			JP 1993-95164	19930331
OTHER SOURCE(S):	MARPAT 122:46490			

GI



I

AB The title inhibitors useful for treatment of cerebral vasospasm contain tryptophans I (R1-R3 = H, C1-6 alkyl, C3-7 cycloalkyl, PhCH2) or their pharmacol. acceptable salts as active ingredients. Hydrolysis of I (R1 = R3 = Me, R2 = CMe3) in 4N HCl in dioxane at room temperature for 2 h gave 98% I (R1 = R3 = Me, R2 = H), which inhibited release of endothelin-1 and big endothelin-1 from aorta in a dose dependent manner. Tablets containing the products were also formulated.
IT 160092-12-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tryptophans as inhibitors for endothelin formation for treatment of cerebral vasospasm)
RN 160092-12-6 CAPLUS
CN L-Tryptophan, N-[[1-[2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentyl]carbonyl]-, α-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:48723 CAPLUS
DOCUMENT NUMBER: 120:48723
TITLE: Inhibition of thermolysin and neutral endopeptidase 24.11 by a novel glutaramide derivative: X-ray structure determination of the thermolysin-inhibitor complex
AUTHOR(S): Holland, D. R.; Barclay, P. L.; Danilewicz, J. C.; Matthews, B. W.; James, K.
CORPORATE SOURCE: Inst. Mol. Biol., Univ. Oregon, Eugene, OR, 97403, USA
SOURCE: Biochemistry (1994), 33(1), 51-6
CODEN: BICHAW; ISSN: 0006-2960
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Determination of the X-ray structure of thermolysin-inhibitor complexes has proven useful in aiding the understanding of the mode of binding of inhibitors of related, physiol. important, mammalian zinc peptidases including neutral endopeptidase EC 3.4.24.11 and angiotensin-converting enzyme. Here the authors describe the mode of binding to crystalline thermolysin of N-(1-(2(R,S)-carboxy-4-phenylbutyl)cyclopentylcarbonyl)-(S)-tryptophan (CCT). CCT is an analog of both candoxatrilat, a potent inhibitor of neutral endopeptidase 24.11, and of the 5-indanyl ester prodrug candoxatril, which is under clin. evaluation as a potential therapy for congestive heart failure. CCT differs from the previously studied N-carboxyalkyl dipeptide CLT [N-(1-carboxy-3-phenylpropyl)-(S)-leucyl-(S)-tryptophan] in several important respects. It has a highly constrained gem-cyclopentyl P1' substituent and lacks the characteristic imino nitrogen substituent of CLT. The structure determination shows that, notwithstanding the conformational influence of the gem-cyclopentyl substituent, CCT binds within the active site of thermolysin in a similar manner to CLT. Although the characteristic hydrogen bond between the imino nitrogen of CLT and thermolysin is absent in CCT, the affinities of the two inhibitors for the enzyme are virtually identical. These results illustrate the importance of considering not only those hydrogen bonds that are formed in an enzyme-ligand complex but also the other hydrogen bonds that may be lost due to desolvation of the enzyme and ligand on formation of the complex. In addition, the overall conformational demands placed upon a ligand in order to achieve receptor interaction may be critically important.

IT **129980-23-0D**, complexes with thermolysin
RL: BIOL (Biological study)
(three-dimensional structure of and hydrogen bonding role in, carboxylalkyl dipeptide complexes in relation to)
RN 129980-23-0 CAPLUS
CN L-Tryptophan, N-[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1993:39409 CAPLUS
DOCUMENT NUMBER: 118:39409
TITLE: Preparation of N-[1-[2- carboxy-3-(prolylamino)propyl]cyclopentane carbonyl]serines and analogs as antihypertensives
INVENTOR(S): Brown, David; Collis, Alan John; Danilewicz, John Christopher; James, Keith; Kobylecki, Ryszard Jurek
PATENT ASSIGNEE(S): Pfizer Ltd., UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9214706	A1	19920903	WO 1992-EP321	19920212

W: CA, FI, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE
PRIORITY APPLN. INFO.: GB 1991-3454 A 19910219
OTHER SOURCE(S): MARPAT 118:39409
GI



AB Title compds. [I; R1, R2 = H, biolabile ester residue; 1 or both of OR1, OR2 may be replaced by NH2; R1 = CHR5(CH2)nOCH2R, alkoxymethyl, furfuryl, (substituted) Ph, etc.; R = (halo)phenyl; R4 = H, OH; R5 = H, Me; n = 0, 1] were prepared Thus, N-tert-butoxycarbonyl-(S)-proline 4-nitrophenyl ester was condensed with 1-[3-amino-2(S)-tert-butoxycarbonylpropyl] cyclopentanecarboxylic acid Na salt and the product condensed with O-benzyl-(S)-serine Me ester to give (S,S)-I (R1 = CMe3, R2 = Me, R3 = CH2OCH2Ph, R4 = H). (S,S)-I (R1 = R2 = R4 = H, R3 = CH2OCH2C6H4F-4) had IC50 of 4.0 + 10-9 and 1.8 + 10-8 M against angiotensin converting enzyme and neutral metalloendopeptidase, resp.

IT **144934-64-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as antihypertensive)
RN 144934-64-5 CAPLUS
CN β-Alanine, 2-[[1-[[(1-carboxy-2-(tetrahydro-2-furanyl)ethyl]amino]carbonyl]cyclopentyl]methyl]-N-L-prolyl- (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1990:591965 CAPLUS
DOCUMENT NUMBER: 113:191965
TITLE: Preparation of N-[1-(3-lysylamino-2-carboxylpropyl)-1-cyclopentanecarbonyl]tyrosine and analogs as cardivascular agents
INVENTOR(S): Danilewicz, John Christopher; James, Keith; Kobylecki, Ryszard Jurek
PATENT ASSIGNEE(S): Pfizer Ltd., UK; Pfizer Inc.
SOURCE: Eur. Pat. Appl., 94 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 358398	A1	19900314	EP 1989-308740	19890830
EP 358398	B1	19930310		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4975444	A	19901204	US 1989-398675	19890825
IL 91460	A1	19950831	IL 1989-91460	19890829
AT 86606	E	19930315	AT 1989-308740	19890830
ES 2054009	T3	19940801	ES 1989-308740	19890830
CA 1341046	A1	20000704	CA 1989-610165	19890901
DK 8904362	A	19900306	DK 1989-4362	19890904
DK 175082	B1	20040524		
FI 8904158	A	19900306	FI 1989-4158	19890904
FI 111715	B1	20030915		
NO 8903546	A	19900306	NO 1989-3546	19890904
NO 177747	B	19950807		
NO 177747	C	19951115		
AU 8941052	A1	19900308	AU 1989-41052	19890904
AU 604195	B2	19901206		
HU 51293	A2	19900428	HU 1989-4562	19890904
HU 215440	B	20000428		
DD 284222	A5	19901107	DD 1989-332345	19890904
ZA 8906760	A	19910424	ZA 1989-6760	19890904
PL 161527	B1	19930730	PL 1989-281295	19890904
RU 2012556	C1	19940515	RU 1989-4614874	19890904
CZ 282142	B6	19970514	CZ 1989-5108	19890904
CN 1040986	A	19900404	CN 1989-106909	19890905
CN 1031051	B	19960221		
JP 02124862	A2	19900514	JP 1989-230253	19890905
JP 06060144	B4	19940810		
RU 2108322	C1	19980410	RU 1993-4970	19930524
PRIORITY APPLN. INFO.:			GB 1988-20844 A	19880905
			EP 1989-308740 A	19890830

OTHER SOURCE(S): MARPAT 113:191965
GI For diagram(s), see printed CA Issue.
AB The title compds. [I; A = atoms to complete an (un)saturated 5- or 6-membered carbocyclic ring; R,R4 = H, alkyl, cycloalkyl, PhCH2, biolabile ester residue; R1 = H, alkyl; R2 = H, aryl, heterocyclyl, amido, carbamoyl, etc.; R3 = 3-indolylmethyl, 3-indazolylmethyl, (un)substituted PhCH2; Y = bond, alkylene], inhibitors of enzyme E. C. 3.4.24.11 and angiotensin converting enzyme (no data), were prepd. Thus, 1-(2-tert-butylcarbonyl-3-dibenzylaminopropyl)-3-dibenzylaminopropyl)-1-cyclopentanecarboxylic acid was condensed with (S)-4-HOC6H4CH(NH2)CO2Me3 to give cyclopentanecarbonyltyrosine ester (S)-II [R = R4 = R5 = CMe3, R2 = N(CH2Ph)2] which was N-deprotected and the product condensed with (S)-QOH [Q = R6NH(CH2)4CH(NHR6)CO; R6 = CO2CH2Ph] to give (S,S,S)-II (R2 = NHQ) (III; R,R4, and R5 same as above, R6 = CO2CH2Ph). The latter was deprotected in 2 steps to give III (R = R4 = R5 = R6 = H).
IT 129980-16-1P 129980-20-7P 129980-23-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of cardiovascular agents)
RN 129980-16-1 CAPLUS
CN 1H-Indazole-3-propanoic acid, α-[[[1-(2-carboxypentyl)cyclopentyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 129980-20-7 CAPLUS
CN L-Tryptophan, N-[[1-(2-carboxypentyl)cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 129980-23-0 CAPLUS
CN L-Tryptophan, N-[[1-(2-carboxy-4-phenylbutyl)cyclopentyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1990:405779 CAPLUS
DOCUMENT NUMBER: 113:5779
TITLE: Spiro-substituted glutaramides as diuretics
INVENTOR(S): Danilewicz, John Christopher
PATENT ASSIGNEE(S): Pfizer Ltd., UK
SOURCE: Brit. UK Pat. Appl., 49 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2218983	A1	19891129	GB 1988-12596	19880527
PRIORITY APPLN. INFO.:			GB 1988-12596	19880527

OTHER SOURCE(S): CASREACT 113:5779; MARPAT 113:5779
GI For diagram(s), see printed CA Issue.
AB The title compds. [I; R = H, C1-6 alkyl, PhCH2, ester residue; R1 = H, C1-4 alkyl; R5 = substituent; A completes a 4-7-membered saturated or mono-unsatd. carbocyclic ring which may be optionally fused to a further saturated or unsatd. 5- or 6-membered carbocyclic ring, X = Q wherein R2, R3 = H, OH, C1-4 alkyl, alkoxy; R4 = H, C2-6 alkyl, PhCH2, ester residue; Y = O, CH2, CH2CH2, Q1 (wherein m, n = 1, 2; q = 3-5)], useful as diuretics in treating such cardiovascular disorders as hypertension and heart failure, are prepared 1-Ethyl-3-(dimethylamino)propylcarbodiimide HCl was added to a stirred mixture of ester II (preparation given), ester salt III (preparation give), 1-hydroxybenzotriazole, and N-methylmorpholine in CH2Cl2 under cooling and stirred at room temperature to give 85% IV. Also prepared were 23 addnl. I and many intermediates. The suitable dose is 10-1500 mg/day for adults.
IT 127283-34-5P 127283-36-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as diuretic)
RN 127283-34-5 CAPLUS
CN Cyclopentanepropanoic acid, 1-[[[6-(hydroxymethyl)-7-oxabicyclo[2.2.1]hept-2-yl]amino]carbonyl]-α-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 127283-36-7 CAPLUS
CN 7-Oxabicyclo[2.2.1]heptane-2-carboxylic acid, 6-[[[1-(2-carboxy-4-methoxybutyl)cyclopentyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



```
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     139.67     301.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -20.44     -20.44

STN INTERNATIONAL LOGOFF AT 11:12:54 ON 03 OCT 2005
```